Infections and Immunity Research Board (IIB)
The Infections and Immunity Research Board is responsible for the MRC’s programmes and funding in basic, clinical and translational research applied to infectious human disease and to disorders of the human immune system, including:
- Virology, bacteriology and parasitology of human pathogens, zoonoses, model infectious agents and vectors of infectious agents;
- Human immunology including studies in humans and informative models;
- Molecular, cellular and systems research into mechanisms of susceptibility, immunity, inflammation, immune tolerance and rejection, pathogenesis, resistance and physiology;
- Discovery research and early stage development of diagnostics, vaccines, immunotherapeutics and vaccines in vitro, including structural biology, animal models and early studies in humans;
- Population-level research, using mathematical, epidemiological, genetic and genomic designs, to elucidate disease risks, aetiologies and progression, and to understand the evolution of pathogen populations;
- Research to inform novel strategies for preventing and controlling infectious and immune disease control, including research on human behaviour and lifestyle;
- Global infections.
All proposals anticipating an MRC expenditure greater than £3 million should be discussed with the named programme manager.
Applicants planning to undertake a genome-wide association study are directed to MRC's GWAS guidance; applicants planning to undertake next generation sequencing studies are directed to MRC's guidance on accessing HTS hubs. Those planning to request support for establishment, maintenance or use of cohort resources should consider the MRC cohort resources guidance.